Peter ten Dijke Group

Peter ten Dijke

Oncode Investigator at LUMC

My Research

Peter ten Dijke, Principal Investigator 1 Research group: Mechanism of TGFb signalling Biography Peter ten Dijke received his Ph.D. degree in 1991 from Wageningen University, The Netherlands based on his research on the identification of the third isoform of TGFβ performed at Oncogene Science, Inc., New York, USA. He did his postgraduate studies with Kohei Miyazono and Carl-Henrik Heldin at the Ludwig Institute for Cancer Research (LICR), Uppsala, Sweden. In 1994, he became group leader at LICR and in 1999 he moved to the Netherlands Cancer Institute, Amsterdam, The Netherlands. In 2005 he moved to the Leiden University Medical Center, Leiden, The Netherlands, and is currently a professor of molecular cell biology at Leiden University.

His laboratory studies how subverted TGF-β family signaling is involved in cancer and vascular diseases, and uses chemical biological approaches to monitor and regulate dynamic signaling processes. Major breakthroughs were the identification of the cell surface receptors for TGF-β, activin and BMP and the inhibitory SMAD7. His contributions to the role of TGF-β in tumor angiogenesis have led to new targeting agents that are clinically tested. His more recent studies have been on the role of reversible modifications of TGF-β receptors with ubiquitin.


  • 2016 EMBO member
  • 2015: Noreen Cunningham lecture award
  • 2015: FEBS national lecture award
  • 2015: Chang Jiang Scholar award from the Chinese Ministry of Education
  • 2010: LUMC Education prize for best course
  • 2006: VICI grant Netherlands Organization for Scientific Research
  • 2005: Honorary Doctor of Medicine Uppsala University, Sweden
  • 1998: Small Fernström prize for promising scientist in Sweden
  • 1992-1993: Long-term EMBO Fellowship

Key publications

  1. Goumans, M. J., Valdimarsdottir, G., Itoh, S., Lebrin, F., Larsson, J., Mummery, C., ... & Ten Dijke, P. (2003). Activin receptor-like kinase (ALK) 1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Molecular cell, 12(4), 817-828.
  2. Nakao, A., Afrakhte, M., Morn, A., Nakayama, T., Christian, J. L., Heuchel, R., ... & Ten Dijke, P. (1997). Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature, 389(6651), 631.
  3. Ten Dijke, P., Yamashita, H., Ichijo, H., Franzen, P., Laiho, M., Miyazono, K., & Heldin, C. H. (1994). Characterization of type I receptors for transforming growth factor-beta and activin. Science, 264(5155), 101-104.
  4. Zhang, L., Zhou, F., Drabsch, Y., Gao, R., Snaar-Jagalska, B. E., Mickanin, C., ... & Ten Dijke, P. (2012). USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nature cell biology, 14(7), 717.
  5. Zhang, L., Zhou, F., de Vinuesa, A. G., de Kruijf, E. M., Mesker, W. E., Hui, L., ... & Sheppard, K. A. (2013). TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis. Molecular cell, 51(5), 559-572.
Contact Information
Peter ten Dijke

Peter ten Dijke

Oncode Investigator

Oncode Investigator

More Research

Research Strategy
Focus and Approach
Over 800 scientists working under a single strategy. Oncode is all about uniting efforts and bringing focus to research.
Support Programme
Our supporting programmes
New plans that help fulfil Oncode's objectives get our full support. Young talents are matched with mentors on the basis of their personal endeavours.
Research Groups
Our Groups
We firmly believe in sharing knowledge. From experienced veterans to talented young researchers, we work together in 61 groups.